Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant

Vaccine

Volumn 28, Issue 44, 2010, Pages 7233-7240

  Zhao, Guangyu ^a,b   Du, Lanying ^c   Xiao, Wenjun ^a   Sun, Shihui ^a   Lin, Yongping ^b   Chen, Min ^b   Kou, Zhihua ^a   He, Yuxian ^c   Lustigman, Sara ^c   Jiang, Shibo ^c   Zheng, Bo Jian ^b   Zhou, Yusen ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c NEW YORK BLOOD CENTER   (United States)

Author keywords

ASP 1; H5N1; M2e; Vaccine

Indexed keywords

HYBRID PROTEIN; INFLUENZA VACCINE; M2E ACTIVATION ASSOCIATED PROTEIN 1 FUSION PROTEIN; M2E3 ACTIVATION ASSOCIATED PROTEIN 1 FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGENIC VARIATION; ARTICLE; CELLULAR IMMUNITY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FEMALE; HUMORAL IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; ONCHOCERCA VOLVULUS; PRIORITY JOURNAL;

EID: 77957821697     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.049     Document Type: Article

References (35)

1. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998, 279(5349):393-396.
2. Guan Y., Smith G.J., Webby R., Webster R.G. Molecular epidemiology of H5N1 avian influenza. Rev Sci Technol 2009, 28(1):39-47.
3. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007, 13(3):426-435.
4. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22(23-24):2993-3003.
5. Mozdzanowska K., Feng J., Eid M., Kragol G., Cudic M., Otvos L., et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003, 21(19-20):2616-2626.
6. De Filette M., Fiers W., Martens W., Birkett A., Ramne A., Lowenadler B., et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 2006, 24(44-46):6597-6601.
7. Pei S., Xiong N., Zhang Y., Chen S. Increasing M2 epitope density enhances systemic and mucosal immune responses to influenza A virus. Biotechnol Lett 2009, 31(12):1851-1856.
8. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5(10):1157-1163.
9. Denis J., Acosta-Ramirez E., Zhao Y., Hamelin M.E., Koukavica I., Baz M., et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26(27-28):3395-3403.
10. Ebrahimi S.M., Tebianian M. Heterologous expression, purification and characterization of the influenza A virus M2e gene fused to Mycobacterium tuberculosis HSP70 (359-610) in prokaryotic system as a fusion protein. Mol Biol Rep 2010, 37(6):2877-2883.
11. Zhang G.G., Li D.X., Zhang H.H., Zeng Y.M., Chen L. Enhancement of mucosal immune response against the M2eHBc+ antigen in mice with the fusion expression products of LTB and M2eHBc+ through mucosal immunization route. Vet Res Commun 2009, 33(7):735-747.
12. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26(2):201-214.
13. Eliasson D.G., El Bakkouri K., Schon K., Ramne A., Festjens E., Lowenadler B., et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 2008, 26(9):1243-1252.
14. MacDonald A.J., Cao L., He Y., Zhao Q., Jiang S., Lustigman S. rOv-ASP-1, a recombinant secreted protein of the helminth Onchocerca volvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens. Vaccine 2005, 23(26):3446-3452.
15. Xiao W., Du L., Liang C., Guan J., Jiang S., Lustigman S., et al. Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines. Vaccine 2008, 26(39):5022-5029.
16. He Y., Barker S.J., MacDonald A.J., Yu Y., Cao L., Li J., et al. Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells. J Immunol 2009, 182(7):4005-4016.
17. Waterhouse A.M., Procter J.B., Martin D.M., Clamp M., Barton G.J. Jalview Version 2 - a multiple sequence alignment editor and analysis workbench. Bioinformatics 2009, 25(9):1189-1191.
18. Zhao G., Lin Y., Du L., Guan J., Sun S., Sui H., et al. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 2010, 7:9.
19. Du L., Zhao G., Lin Y., Sui H., Chan C., Ma S., et al. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol 2008, 180(2):948-956.
20. Chen Q., Kuang H., Wang H., Fang F., Yang Z., Zhang Z., et al. Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus Genes 2009, 38(1):30-38.
21. Patel A., Tran K., Gray M., Li Y., Ao Z., Yao X., et al. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 2009, 27(23):3083-3089.
22. Liu W., Peng Z., Liu Z., Lu Y., Ding J., Chen Y.H. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 2004, 23(3):366-371.
23. De Filette M., Martens W., Roose K., Deroo T., Vervalle F., Bentahir M., et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 2008, 283(17):11382-11387.
24. Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988, 62(8):2762-2772.
25. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004, 172(9):5598-5605.
26. Mozdzanowska K., Maiese K., Furchner M., Gerhard W. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 1999, 254(1):138-146.
27. Wang R., Song A., Levin J., Dennis D., Zhang N.J., Yoshida H., et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 2008, 80(2):168-177.
28. Wu F., Yuan X.Y., Li J., Chen Y.H. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. Vaccine 2009, 27(32):4320-4324.
29. Subbarao K., Luke C. H5N1 viruses and vaccines. PLoS Pathog 2007, 3(3):e40.
30. Keitel W.A., Atmar R.L. Vaccines for pandemic influenza: summary of recent clinical trials. Curr Top Microbiol Immunol 2009, 333:431-451.
31. Wu F., Yuan X.Y., Huang W.S., Chen Y.H. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine. Vaccine 2009, 27(43):6095-6101.
32. Schotsaert M., De Filette M., Fiers W., Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009, 8(4):499-508.
33. Cheung C.Y., Poon L.L., Lau A.S., Luk W., Lau Y.L., Shortridge K.F., et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?. Lancet 2002, 360(9348):1831-1837.
34. Chan M.C., Cheung C.Y., Chui W.H., Tsao S.W., Nicholls J.M., Chan Y.O., et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 2005, 6:135.
35. Zheng B.J., Chan K.W., Lin Y.P., Zhao G.Y., Chan C., Zhang H.J., et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008, 105(23):8091-8096.